Neutralising antibodies to interferon beta during the treatment of multiple sclerosis

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Journal of Neurology Neurosurgery & Psychiatry

• Publication date

  2002-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1136/jnnp.73.5.465PMID 12397132PMCID PMC1738139
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Multiple Sclerosis

  2007cited by this paper
• Goal setting and attainment in Alzheimer’s disease patients treated with donepezil

  2002cited by this paper
• The neural basis of Charles Bonnet hallucinations: a hypothesis

  2002cited by this paper
• Relation between medial temporal atrophy and functional brain activity during memory processing in Alzheimer’s disease: a combined MRI and SPECT study

  2002cited by this paper
• van Swieten’s concept of cerebral embolic stroke

  2002cited by this paper
• Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN).

  2002cited by this paper
• Long term outcome of temporal lobe epilepsy surgery: analyses of 140 consecutive patients

  2002cited by this paper
• Monthly corticosteroids decrease neutralizing antibodies to IFNβ1b: a randomized trial in multiple sclerosis

  2002cited by this paper
• Functional Imaging of Visuospatial Processing in Alzheimer's Disease

  2002cited by this paper
• Serum IFN neutralizing antibodies and neopterin levels in a cross-section of MS patients

  2001cited by this paper
• PRISMS-4: Long-term efficacy of interferon-&bgr;-1a in relapsing MS

  2001cited by this paper
• Interferon-beta (IFN-β) antibodies in interferon-β1a-and interferon-β1b-treated multiple sclerosis patients. Prevalence, kinetics, cross-reactivity, and factors enhancing interferon-β immunogenicity in vivo

  2001cited by this paper
• Study of binding and neutralising antibodies to interferon-β in two groups of relapsing-remitting multiple sclerosis patients

  2001cited by this paper
• Interferon-beta (INF-beta) antibodies in interferon-beta1a- and interferon-beta1b-treated multiple sclerosis patients. Prevalence, kinetics, cross-reactivity, and factors enhancing interferon-beta immunogenicity in vivo.

  2001influential reference
• Randomized controlled trial of interferon- beta-1a in secondary progressive MS

  2001cited by this paper
• The significance of neutralizing antibodies in patients with multiple sclerosis treated with interferon beta.

  2001cited by this paper
• Randomized controlled trial of interferon-beta-1a in secondary progressive MS

  2001cited by this paper
• Seizure Outcome after Temporal Lobectomy: Current Research Practice and Findings

  2001cited by this paper
• A randomized, controlled trial of surgery for temporal-lobe epilepsy.

  2001cited by this paper
• Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group.

  2000influential reference
• Hemophilia treatment. Factor VIII inhibitors with recombinant products: prospective clinical trials.

  2000cited by this paper
• Interleukin-1 receptor antagonist, soluble tumor necrosis factor-a receptor type I and II, and soluble E-selectin serum levels in multiple sclerosis patients receiving weekly intramuscular injections of interferon-b1a.

  2000cited by this paper
• Neutralizing antibodies to interferon (IFN) alpha-2a and IFN beta-1a or IFN beta-1b in MS are not cross-reactive.

  2000cited by this paper
• Immunogenicity of interferon‐β in multiple sclerosis patients: Influence of preparation, dosage, dose frequency, and route of administration

  2000cited by this paper
• Neutralizing and binding anti‐interferon‐β (IFN‐β) antibodies. A comparison between IFN‐β‐1a and IFN‐β‐1b treatment in multiple sclerosis

  2000cited by this paper
• Multiple sclerosis.

  2000cited by this paper
• Neutralizing antibodies to interferon (IFN) α-2a and IFN β-1a or IFN β-1b in MS are not cross-reactive

  2000cited by this paper
• Failed surgery for epilepsy. A study of persistence and recurrence of seizures following temporal resection.

  2000cited by this paper
• Inhibitor Antibodies to Factor VIII and Factor IX: Management

  2000cited by this paper
• Immunogenicity of interferon-beta in multiple sclerosis patients: influence of preparation, dosage, dose frequency, and route of administration. Danish Multiple Sclerosis Study Group.

  2000influential reference
• Interleukin-1 receptor antagonist, soluble tumor necrosis factor-alpha receptor type I and II, and soluble E-selectin serum levels in multiple sclerosis patients receiving weekly intramuscular injections of interferon-beta1a.

  2000cited by this paper
• Assessment Scales in Old Age Psychiatry

  2000cited by this paper
• Does the migraine aura reflect cortical organization?

  2000cited by this paper
• Hemophilia factor VIII therapy. Immunological tolerance. A clinical perspective.

  2000cited by this paper
• Interferon-α2a reduces MRI disease activity in relapsing-remitting multiple sclerosis

  1999cited by this paper
• The perceptual consequences of visual loss: 'positive' pathologies of vision.

  1999cited by this paper
• Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies

  1999influential reference
• Evidence of interferon beta-1a dose response in relapsing-remitting MS: the OWIMS Study. The Once Weekly Interferon for MS Study Group.

  1999influential reference
• Neocortical and hippocampal glucose hypometabolism following neurotoxic lesions of the entorhinal and perirhinal cortices in the non-human primate as shown by PET. Implications for Alzheimer's disease.

  1999cited by this paper
• Interferon-alpha2a reduces MRI disease activity in relapsing-remitting multiple sclerosis. Norwegian Study Group on Interferon-alpha in Multiple Sclerosis.

  1999cited by this paper
• Comparative pharmacokinetics and pharmacodynamics of recombinant human interferon beta‐1a after intramuscular and subcutaneous administration

  1999cited by this paper
• Pharmacodynamic Comparison of Single Doses of IFN-beta 1a and IFN-beta 1b in Healthy Volunteers

  1999cited by this paper
• The evolution of neutralizing antibodies in multiple sclerosis patients treated with interferon β-1b

  1999cited by this paper
• Natural killer cells in relapsing-remitting MS: effect of treatment with interferon beta-1B.

  1999cited by this paper
• Further study on the specificity and incidence of neutralizing antibodies to interferon (IFN) in relapsing remitting multiple sclerosis patients treated with IFN beta-1a or IFN beta-1b.

  1999cited by this paper
• Natural killer cells in relapsing-remitting MS

  1999cited by this paper
• Results of an Ongoing, Open-Label, Safety-Extension Study of Interferon Beta-1a (Avonex) Treatment in Multiple Sclerosis

  1999cited by this paper
• Assessment Scales in old Age Psychiatry

  1999cited by this paper
• A Novel Bioassay for the Determination of Neutralizing Antibodies to IFNβ1b

  1998cited by this paper
• Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS.

  1998cited by this paper
• Structural and Functional Differences Between Glycosylated and Non-glycosylated Forms of Human Interferon-β (IFN-β)

  1998cited by this paper
• Development of neutralizing antibodies in patients with relapsing-remitting multiple sclerosis treated with IFN-beta1a.

  1998cited by this paper
• Development of Neutralizing Antibodies in Patients with Relapsing-Remitting Multiple Sclerosis Treated with IFN-β1a

  1998cited by this paper
• Structural and functional differences between glycosylated and non-glycosylated forms of human interferon-beta (IFN-beta).

  1998cited by this paper
• Role of anti-interferon antibodies in breakthrough occurrence during alpha 2a and 2b therapy in patients with chronic hepatitis C.

  1998cited by this paper
• Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis

  1998influential reference
• Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group.

  1998cited by this paper
• Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

  1998cited by this paper
• A novel bioassay for the determination of neutralizing antibodies to IFN-beta1b.

  1998cited by this paper
• Neutralizing antibodies to interferon beta-1a and interferon beta-1b in MS patients are cross-reactive.

  1998cited by this paper
• Placebo-controlled multicentre randomised trial of interferon β-1b in treatment of secondary progressive multiple sclerosis

  1998cited by this paper
• Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis

  1997cited by this paper
• Neutralizing antibodies and the efficacy of interferon beta-1b in relapsing-remitting multiple sclerosis

  1997cited by this paper
• Clinical experience of antibodies to interferon-alpha during treatment of chronic myeloid leukemia.

  1997cited by this paper
• Interferon beta in multiple sclerosis. Current policy is sensible.

  1997cited by this paper
• Role of interferons in demyelinating diseases.

  1997cited by this paper
• Cytolytic activity of peripheral blood blast cells from patients with acute myeloid leukemia.

  1997cited by this paper
• Interferon immunogenicity: technical evaluation of interferon-alpha 2a.

  1997cited by this paper
• Causality, the menopause, and depression

  1997cited by this paper
• Clinical Global Impressions in Alzheimer's Clinical Trials

  1996cited by this paper
• Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis

  1996cited by this paper
• Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b

  1996cited by this paper
• Use of Goal Attainment Scaling to measure treatment effects in an anti-dementia drug trial.

  1996cited by this paper
• Immune-mediated side-effects of cytokines in humans.

  1995cited by this paper
• Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group.

  1995cited by this paper
• Interferon Antibodies in Thrombocythemia

  1994cited by this paper
• The Clinician Interview‐ Based Impression (CIBI)

  1994cited by this paper
• Role of aggregated human growth hormone (hGH) in development of antibodies to hGH.

  1980cited by this paper
• THE ANTIGENICITY OF INSULIN: A REVIEW.

  1964cited by this paper
• The antigenicity of insulin: a review.

  1962cited by this paper

• Effect of Treatment on Steroidome in Women with Multiple Sclerosis

  2025cites this paper
• Intranasal neomycin evokes broad-spectrum antiviral immunity in the upper respiratory tract

  2024cites this paper
• Engineering antigen-specific tolerance to an artificial protein hydrogel

  2023cites this paper
• A Short 5′triphosphate RNA nCoV-L Induces a Broad-Spectrum Antiviral Response by Activating RIG-I

  2022cites this paper
• A stem-loop RNA RIG-I agonist confers prophylactic and therapeutic protection against acute and chronic SARS-CoV-2 infection in mice

  2021cites this paper
• Classification and visualization of longitudinal patterns of medication dose: An application to interferon‐beta‐1a and amitriptyline in patients with multiple sclerosis

  2021cites this paper
• Effects of Interferon Beta in COVID-19 adult patients: Systematic Review

  2021cites this paper
• A stem-loop RNA RIG-I agonist protects against acute and chronic SARS-CoV-2 infection in mice

  2021cites this paper
• Interferon β-1a and β-1b for patients with multiple sclerosis: updates to current knowledge

  2018cites this paper
• Watching the gorilla and questioning delivery dogma.

  2017cites this paper
• Comparative efficacy of disease-modifying therapies for patients with relapsing remitting multiple sclerosis: Systematic review and network meta-analysis.

  2016cites this paper
• Interferon Beta: From Molecular Level to Therapeutic Effects.

  2016cites this paper
• An Albumin-Free Formulation for Escherichia coli-Derived Interferon Beta-1b with Decreased Immunogenicity in Immune Tolerant Mice

  2016cites this paper
• Interactions between therapeutic protein formulations and surfaces

  2015cites this paper
• Do neutralising antibodies against exogenous interferon-beta inhibit endogenous signalling pathways?

  2015cites this paper
• Development of interferon beta-neutralising antibodies in multiple sclerosis—a systematic review and meta-analysis

  2015cites this paper
• Novel diagnostic tools and solutions for multiple sclerosis treatment: a patent review (2009 – 2014)

  2015cites this paper
• Characterization and quantitation of aggregates and particles in interferon-β products: potential links between product quality attributes and immunogenicity.

  2013cites this paper
• Interferon-beta therapy in multiple sclerosis: the short-term and long-term effects on the patients’ individual gene expression in peripheral blood

  2013cites this paper
• SWEET-HOME ICT technologies for the assessment of elderly subjects

  2013cites this paper
• [Biomarkers in multiple sclerosis].

  2013cites this paper
• Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis.

  2012cites this paper
• MxA Gene Expression Analysis as an Interferon-β Bioactivity Measurement in Patients with Multiple Sclerosis and the Identification of Antibody-Mediated Decreased Bioactivity

  2012cites this paper
• Variability in detection and quantification of interferon β-1b–induced neutralizing antibodies

  2012cites this paper
• Computational analysis of high-density peptide microarray data with application from systemic sclerosis to multiple sclerosis.

  2012cites this paper
• Neutralizing antibodies are associated with a reduction of interferon-β efficacy during the treatment of Japanese multiple sclerosis patients.

  2012cites this paper
• Reassessment of Blood Gene Expression Markers for the Prognosis of Relapsing-Remitting Multiple Sclerosis

  2011cites this paper
• Second-line disease modifying treatments for multiple sclerosis

  2011cites this paper
• Frequency and Magnitude of Interferon β Neutralizing Antibodies in the Evaluation of Interferon β Immunogenicity in Patients with Multiple Sclerosis

  2011cites this paper
• Interferon beta treatment: Bioavailability and antiviral activity in multiple sclerosis patients

  2011cites this paper
• Predictive factors of neutralizing antibodies development in relapsing-remitting multiple sclerosis patients on interferon Beta-1b therapy

  2011cites this paper
• Neutralizing antibodies, MxA expression and MMP‐9/TIMP‐1 ratio as markers of bioavailability of interferon‐beta treatment in multiple sclerosis patients: a two‐year follow‐up study

  2010cites this paper
• Neutralizing antibodies and the biological response to interferon-beta therapy

  2010cites this paper
• On the Role of Aggregates in the Immunogenicity of Recombinant Human Interferon Beta in Patients with Multiple Sclerosis

  2010cites this paper
• Hybrid transgenic immune tolerant mouse model for assessing the breaking of B cell tolerance by human interferon beta.

  2010cites this paper
• Unwanted immunogenicity: lessons learned and future challenges.

  2010cites this paper
• The ADAS‐cog and clinically meaningful change in the VISTA clinical trial of galantamine for Alzheimer's disease

  2010cites this paper
• Multiple sclerosis: a practical overview for clinicians.

  2010cites this paper
• A safety review of topical bovine thrombin-induced generation of antibodies to bovine proteins.

  2009cites this paper
• Lack of interferon‐beta bioactivity is associated with the occurrence of relapses in multiple sclerosis

  2009cites this paper
• Implications of neutralising antibodies on therapeutic efficacy.

  2009cites this paper
• High-dose, high-frequency recombinant interferon beta-1a in the treatment of multiple sclerosis.

  2009cites this paper
• High-dose, high-frequency recombinant interferon beta-1a in the treatment of multiple sclerosis

  2009cites this paper
• Neutralizing antibodies against interferon beta: fluctuation is modest and titre dependent

  2009cites this paper
• Validating parameters of a luciferase reporter gene assay to measure neutralizing antibodies to IFNbeta in multiple sclerosis patients.

  2008cites this paper
• Efficacy and tolerability of intramuscular interferon beta-1a compared with subcutaneous interferon beta-1a in relapsing MS: results from PROOF

  2008cites this paper
• Modulation of IFNAR1 mRNA expression in multiple sclerosis patients.

  2008cites this paper
• Comparative study of four different assays for the detection of binding antibodies against interferon-β

  2008cites this paper
• Current Evidence and Therapeutic Strategies for Multiple Sclerosis

  2008cites this paper
• Development of a bioassay for quantification of neutralising antibodies against human interferon-beta in mouse sera.

  2008cites this paper
• Cost-effectiveness of Four Immunomodulatory Therapies for Relapsing-Remitting Multiple Sclerosis: A Markov Model Based on Long-term Clinical Data

  2007cites this paper
• IFNβ bioavailability in multiple sclerosis patients: MxA versus antibody-detecting assays

  2007cites this paper
• Effects of a Step-Therapy Program for Angiotensin Receptor Blockers on Antihypertensive Medication Utilization Patterns and Cost of Drug Therapy

  2007cites this paper
• Effect of Culture Conditions on Glycosylation of Recombinant beta-Interferon in CHO Cells

  2007cites this paper
• Testing for neutralizing antibodies

  2007cites this paper
• In vivo bioactivity of interferon-beta in multiple sclerosis patients with neutralising antibodies is titre-dependent

  2007cites this paper
• Interferon-beta antibodies have a higher affinity in patients with neutralizing antibodies compared to patients with non-neutralizing antibodies.

  2006cites this paper
• Qualitative and quantitative analysis of antibody response against IFNbeta in patients with multiple sclerosis.

  2006cites this paper
• Laboratory Monitoring of Cytokine Therapy

  2006cites this paper
• Neutralising antibodies to IFN-β in patients with multiple sclerosis

  2006cites this paper
• Should neutralizing antibodies be monitored during interferon-β treatment for multiple sclerosis?

  2006cites this paper
• Collaborative goal technology: theory & practice

  2006cites this paper
• Measuring and evaluating interferon b-induced antibodies in patients with multiple sclerosis

  2006cites this paper
• Is there or is there not a place for anti-interferon antibodies in the decision making of multiple sclerosis treatment optimisation?

  2006cites this paper
• Neutralising antibodies to IFN-beta in patients with multiple sclerosis.

  2006cites this paper
• Differing immunogenic potentials of interferon beta preparations in multiple sclerosis patients

  2006cites this paper
• Qualitative and quantitative analysis of antibody response against IFNβ in patients with multiple sclerosis

  2006cites this paper
• Eight-year immunogenicity and safety of interferon beta-1a-Avonex®treatment in patients with multiple sclerosis

  2005cites this paper
• Interferon β-1a in MS

  2005cites this paper
• Immune response to immunotherapy: the role of neutralising antibodies to interferon beta in the treatment of multiple sclerosis.

  2005cites this paper
• Interferon-β1b in the treatment of multiple sclerosis

  2005cites this paper
• [Long-term effect of neutralizing antibodies to interferon beta-1 b in patients with multiple sclerosis].

  2005cites this paper
• Significance of neutralizing antibodies to interferon beta during treatment of multiple sclerosis: expert opinions based on the Proceedings of an International Consensus Conference

  2005cites this paper
• Pharmacogenomics of responsiveness to interferon IFN‐β treatment in multiple sclerosis: A genetic screen of 100 type I interferon‐inducible genes

  2005cites this paper
• The importance of measuring IFNβ bioactivity: Monitoring in MS patients and the effect of anti-IFNβ antibodies

  2005cites this paper
• Efecto a largo plazo de los anticuerpos neutralizantes de interferón beta-1 b en pacientes con esclerosis múltiple

  2005cites this paper
• Guidelines on use of anti‐IFN‐β antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN‐β antibodies in multiple sclerosis

  2005cites this paper
• Development of a Transgenic Mouse Model Immune Tolerant for Human Interferon Beta

  2005cites this paper
• The importance of measuring IFNbeta bioactivity: monitoring in MS patients and the effect of anti-IFNbeta antibodies.

  2005cites this paper
• Multiple sclerosis patients and immunomodulation therapies: the potential role of new MRI techniques to assess responders versus non-responders

  2005cites this paper
• Neutralizing antibodies against IFN-beta in multiple sclerosis: antagonization of IFN-beta mediated suppression of MMPs.

  2004cites this paper
• Neutralizing antibodies to disease-modifying agents in the treatment of multiple sclerosis

  2004cites this paper
• Demyelinating diseases Neutralizing antibodies to beta-IFN: implications forMSmanagement Review:Neutralizingantibodies to interferonbeta: implications for the management of multiple sclerosis (pp 241–246)

  2004cites this paper
• Beneficial effect of interferon-β 1b treatment in patients with relapsing-remitting multiple sclerosis is associated with an increase in serum levels of soluble HLA-I molecules during the first 3 months of therapy

  2004cites this paper
• Management of Secondary-Progressive Multiple Sclerosis

  2004cites this paper
• Optimising MS disease-modifying therapies: antibodies in perspective

  2004cites this paper
• Stabilization of rapidly worsening multiple sclerosis for 36 months in patients treated with interferon beta plus cyclophosphamide followed by interferon beta

  2004cites this paper
• Neutralizing antibodies to interferon beta: implications for the management of multiple sclerosis

  2004cites this paper
• Corticosteroids treatment.

  2004cites this paper
• Immunological effects of interferon-beta and glatiramer acetate in multiple sclerosis

  2004cites this paper
• Neutralizing antibodies against IFN-β in multiple sclerosis: antagonization of IFN-β mediated suppression of MMPs

  2004cites this paper
• Epitope Specificity of Neutralizing Antibodies Against IFN-β

  2004cites this paper
• Interferon-beta: the neutralizing antibody (NAb) titre predicts reversion to NAb negativity

  2004cites this paper
• Benefit-risk assessment of interferon-b therapy for relapsing multiple sclerosis

  2004cites this paper
• Neutralization of the biological activity of cytokines and other protein effectors by antibody: theoretical formulation of antibody titration curves in relation to antibody affinity.

  2003cites this paper
• Long-term evolution of anti-INFβ antibodies in IFNβ-treated MS patients

  2003cites this paper
• Neutralising antibodies to interferon beta.

  2003cites this paper
• Strategies to treat and prevent the development of neutralizing anti-interferon-beta antibodies.

  2003cites this paper
• Radiofrequency neurotomy.

  2003cites this paper
• Long-term evolution of anti-INFbeta antibodies in IFNbeta-treated MS patients: the London, Canada, MS Clinic experience.

  2003cites this paper